LeonaBio (LONA) Return on Capital Employed (2020 - 2026)
LeonaBio (LONA) reported Return on Capital Employed of 146.19% for Q1 2026, up 3506.0% year-over-year from 4.05% in Q1 2025, and up 80.57% quarter-over-quarter from 752.56% in Q4 2025.
LeonaBio (LONA) Return on Capital Employed (2020 - 2026) Analysis & Trends
LeonaBio (LONA) has 7 years of Return on Capital Employed data on file, last reported at 146.19% in Q1 2026.
- Return on Capital Employed for Q1 2026 came in at 146.19%, up 3506.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 146.19% (up 3506.0% YoY), and the FY2025 annual result was 365.73%, down 26104.0% from the prior year.
- Return on Capital Employed advanced to 146.19% in Q1 2026 per LONA's latest filing, from 752.56% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 24.48% in Q1 2022 and troughed at 752.56% in Q4 2025.
- A 5-year average of 137.67% and a median of 101.76% in 2024 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2025 and 2026: Return on Capital Employed tumbled 58263 bps in 2025, then jumped 3506 bps in 2026.
- A 5-year view of Return on Capital Employed shows it stood at 42.5% in 2022, then slumped by 106 bps to 87.35% in 2023, then slumped by 95 bps to 169.93% in 2024, then sank by 343 bps to 752.56% in 2025, then surged by 81 bps to 146.19% in 2026.
- Business Quant data shows LONA's Return on Capital Employed at 146.19% in Q1 2026, 752.56% in Q4 2025, and 130.88% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 450.31% |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 51.73% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -107.40% |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -50.43% |
| 10 | LeonaBio | 154.12 Mn | 86.44 Mn | - | -146.19% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -146.19% |
| Dec 31, 2025 | -752.56% |
| Sep 30, 2025 | -130.88% |
| Jun 30, 2025 | -169.68% |
| Mar 31, 2025 | -181.26% |
| Dec 31, 2024 | -169.93% |
| Sep 30, 2024 | -161.06% |
| Jun 30, 2024 | -125.48% |
| Mar 31, 2024 | -101.76% |
| Dec 31, 2023 | -87.35% |
| Sep 30, 2023 | -77.13% |
| Jun 30, 2023 | -59.61% |
| Mar 31, 2023 | -49.00% |
| Dec 31, 2022 | -42.50% |
| Sep 30, 2022 | -32.94% |
| Jun 30, 2022 | -28.54% |
| Mar 31, 2022 | -24.48% |
| Dec 31, 2021 | -19.38% |
| Sep 30, 2021 | -15.78% |
| Jun 30, 2021 | -12.29% |